Valneva SE (VALN) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects a concerning financial situation with significant losses and negative EBITDA. Despite promising vaccine developments, uncertainties around timelines and guidance, particularly regarding the Lyme disease vaccine, contribute to a negative outlook. Management's inability to provide clear updates and reliance on Pfizer for key information further exacerbates investor concerns. The financial guidance and strategic plans do not offset the current financial losses, leading to a negative sentiment.
Key Financial Performance
Total revenues EUR 170 million, slightly above 2024 levels. Reasons for change include foreign exchange headwinds, planned reduction in third product sales, and growth in proprietary travel vaccine portfolio.
Cash position Nearly EUR 110 million. Enhanced financial flexibility through successful debt refinancing.
Operating cash burn Reduced by more than 20%. Driven by disciplined cash management.
Total product sales EUR 157.9 million, a decrease of 3.3% over 2024 or 1.3% at constant currency. Decrease due to planned reduction in third-party sales and adverse currency impact.
Proprietary product sales Grew by 9% year-over-year (excluding currency effects).
IXIARO sales EUR 98.4 million, up 4.6% or 7.2% at constant currency. Growth driven by the travel segment.
DUKORAL sales EUR 31.9 million, down 1.2% or up 1.8% at constant currency. Impacted by distributor change in Germany.
IXCHIQ sales EUR 8.4 million, up from EUR 3.7 million in 2024. Includes supply of 40,000 doses to French Island La Réunion.
Third-party sales Reduced from EUR 33.2 million to EUR 19.2 million. Decrease due to planned termination of distribution contracts for third-party products.
Other revenues Increased from EUR 6.3 million to EUR 16.8 million. Driven by EUR 10 million revenue recognition related to the Lyme agreement with Pfizer.
Cost of goods and services Increased by EUR 8.6 million. Impacted by EUR 8.5 million inventory write-off related to IXCHIQ and EUR 10.8 million of idle costs.
Research and development expenses Increased from EUR 74.1 million in 2024 to EUR 85.3 million in 2025. Driven by higher spend in Phase II Shigella vaccine candidates and increased R&D investment in chikungunya vaccine.
Marketing and distribution expenses EUR 37.4 million, down from EUR 52.4 million in 2024. Decrease due to reduced IXCHIQ spend.
G&A expenses Decreased from EUR 42.8 million to EUR 37.3 million. Result of initiatives to decrease administrative spend.
Operating loss EUR 82.1 million, compared to an operating profit of EUR 13.3 million in 2024. 2024 profit driven by nonrecurring income from the sale of a priority review voucher.
Loss for the period EUR 115.2 million.
Adjusted EBITDA Minus EUR 51.4 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Lyme Disease Vaccine Candidate (VLA15): Advanced to pivotal Phase III trials with Pfizer partnership. Targeting a large population with no current vaccine available. Data expected in the first half of 2026.
Chikungunya Vaccine (IXCHIQ): Initiated pilot vaccination campaign in Brazil. Focused on post-marketing effectiveness studies and expanding access in low and middle-income countries.
Shigella Vaccine Candidate (S4V2): Phase II studies ongoing, targeting travel and children in low-income countries. Data expected mid-2026.
Geographic Expansion for IXCHIQ: Launched in Brazil and supplied doses to French Island La Réunion. Expanding manufacturing and distribution in low and middle-income countries.
Revenue Performance: Total revenues exceeded EUR 170 million in 2025, with EUR 160 million from product sales. Proprietary product sales grew by 9% year-over-year.
Cost Management: Achieved over 20% reduction in operating cash burn through disciplined cash management.
Strategic Evolution: Focused on becoming a leading vaccine biotech company by growing commercial business, optimizing cash generation, and leveraging R&D capabilities.
Pipeline Expansion: Plans to expand beyond vector-borne diseases, targeting assets like AMR and EBV programs, subject to positive Lyme vaccine data.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Geopolitical Uncertainty: The company faced challenges due to geopolitical uncertainty, which could impact operations and market conditions.
Rising Vaccine Hesitancy: Increasing vaccine hesitancy poses a risk to the adoption and sales of the company's vaccine products.
Biotech Sector Consolidation: Further consolidation in the biotech sector could increase competitive pressures and limit opportunities for smaller players like Valneva.
Foreign Exchange Headwinds: Adverse currency impacts affected revenue, particularly in product sales.
Reduction in Third-Party Product Sales: Planned reduction in third-party product sales led to a decrease in overall revenue.
Inventory Write-Offs: EUR 8.5 million inventory write-offs related to IXCHIQ impacted cost of goods and financial performance.
Manufacturing Challenges: DUKORAL gross margin deteriorated due to manufacturing batch failures, impacting profitability.
R&D Investment Costs: Increased R&D expenses for Phase II Shigella vaccine and post-marketing obligations for chikungunya vaccine added financial strain.
Debt Refinancing Costs: Refinancing debt with Pharmakon incurred additional financial expenses.
Operating Loss: The company reported an operating loss of EUR 82.1 million, driven by nonrecurring income in the prior year and increased costs.
Dependence on Lyme Disease Vaccine Approval: Future financial sustainability and profitability heavily depend on the successful approval and commercialization of the Lyme disease vaccine.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic evolution: Valneva aims to become the leading vaccine biotech company by growing its commercial business, optimizing cash generation, and leveraging its integrated business model for R&D progression.
Lyme disease vaccine (VLA15): Valneva is conducting a Phase III study (VALOR) with approximately 10,000 participants. Results are expected in the first half of 2026. If approved, it will be the first vaccine for Lyme disease, targeting a broad population and potentially included in routine immunization schedules.
Chikungunya vaccine (IXCHIQ): Valneva is investing in post-marketing effectiveness studies and expanding manufacturing and distribution partnerships in low and middle-income countries. A pilot vaccination campaign is ongoing in Brazil.
Shigella vaccine (S4V2): Valneva is conducting two Phase II studies, with data expected mid-2026. The vaccine targets shigellosis, a life-threatening disease, and has potential markets in travel and children in low-income countries.
Financial outlook for 2026: Total product sales are expected to range between EUR 145 million and EUR 160 million, with total revenues between EUR 155 million and EUR 170 million. Growth in proprietary products is anticipated, while third-party product sales will decrease.
Lyme disease vaccine approval impact: A successful approval and commercialization of the Lyme disease vaccine could make Valneva financially self-sustainable and potentially profitable.
Future R&D pipeline expansion: Valneva plans to expand its R&D pipeline beyond vector-borne diseases, targeting innovative vaccine assets and accelerating preclinical programs, subject to positive Lyme disease vaccine data.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Do you still see potential for a Lyme data readout by the end of the first quarter, or could it get pushed to the second quarter?
A:Thomas Lingelbach stated that Pfizer is responsible for the Phase III study and execution, and Valneva is fully blinded. The official guidance from Pfizer is for a data readout in the first half of the year, and they cannot provide a different timeline.
Q:When was the last time you spoke with Pfizer on the Lyme program, and what is the latest communication regarding status and timing?
A:Thomas Lingelbach mentioned that there is a joint development structure with formalized governance, and they have weekly interactions with Pfizer. So far, everything is progressing well.
Q:What gives you confidence that VLA15 will be equally efficacious in serotypes 2 through 6 versus serotype 1?
A:Thomas Lingelbach explained that preclinical models, including passive and active immunization, have shown efficacy across all serotypes. While there is no human data bridging immunological response with efficacy for serotypes 2 through 6, animal models have shown non-inferiority or superiority after three doses compared to a LYMErix biosimilar. The immunological profile observed in clinical studies also supports confidence.
Q:How do you think about capital allocation going forward if Lyme is successful?
A:Peter Buhler stated that upon positive Phase III data, no milestones will be received until first commercial sales, which are at least 1.5 years away. In the short term, the capital profile will not change significantly. They plan to accelerate and augment their pipeline carefully over time.
Q:What is the threshold for Valneva moving forward with full development responsibility for Shigella, S4V2?
A:Thomas Lingelbach stated that the program includes a controlled human infection model in adults to assess pilot efficacy and immunogenicity. If pilot efficacy and a decent level of correlation between immunological response and protection are observed, the program will progress. Otherwise, it will be terminated.
Q:When do you expect to receive an ACIP recommendation for VLA15, if approved, and do you believe a broad recommendation is achievable?
A:Thomas Lingelbach stated that predicting ACIP meetings and outcomes is challenging. Pfizer is expected to progress quickly post-approval. Key criteria for a broad recommendation include risk-benefit analysis, safety profile, efficacy in target groups, and health economic benefits. They are optimistic about a broad recommendation for high-risk populations in high-risk areas.
Q:What should we expect in terms of endpoints or information in the top-line press release for Lyme?
A:Thomas Lingelbach stated that the top-line data will include the primary endpoint and safety. Any additional information disclosed will be at Pfizer's discretion, and Valneva currently has no information on what else may be included.
Q:What is the status of the DoD contract for IXIARO?
A:Thomas Lingelbach confirmed that they expect a new contract this year. Shipments are continuing under the old contract, and the new contract is included in their 2026 revenue guidance.
Q:Could you help us understand the gross margin progression in 2026 and the impact of idle capacity costs?
A:Peter Buhler explained that gross margins for IXIARO are stable, but DUKORAL was impacted by batch write-offs. Idle capacity costs of approximately EUR 10 million are expected to persist unless there are major changes in manufacturing facility usage. The DoD contract is included in the 2026 revenue guidance.
Q:What are the next steps in Asia following the suspension of the SII licensing deal for IXCHIQ?
A:Thomas Lingelbach stated that Valneva is taking control of commercialization and manufacturing in Asia. They are evaluating potential partners, commercialization structures, and manufacturing strategies, with announcements expected later this year.
Q:Could you clarify if the first cohort of participants in the Phase III Lyme study received a booster prior to the last peak season?
A:Thomas Lingelbach stated that a second booster (dose 5) is not currently included but may be added in the future. It will not be part of the initial licensure process but could be included in a supplemental filing.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the timing of the Lyme data readout, stating that they are fully blinded and relying on Pfizer's official guidance. Additionally, they did not provide clarity on the specific content of the top-line press release for Lyme, deferring to Pfizer's discretion.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
American site
Cost good
EUR decrease
EUR income
EUR increase
Phase II
Shigella vaccine
child
contract
currency
debt
extent
finger
good EUR
hand side
income country
investment
model
order
partner Pfizer
party sale
population
portfolio
priority review
process
reduction party
revenue EUR
sale EUR
sale travel
sector
shigellosis
spend
summary
termination
travel segment
travel vaccine
write
VALN Transcript
Valneva SE (VALN) Q4 2025 Earnings Call Transcript
Unknown3-18
The earnings call reflects a concerning financial situation with significant losses and negative EBITDA. Despite promising vaccine developments, uncertainties around timelines and guidance, particularly regarding the Lyme disease vaccine, contribute to a negative outlook. Management's inability to provide clear updates and reliance on Pfizer for key information further exacerbates investor concerns. The financial guidance and strategic plans do not offset the current financial losses, leading to a negative sentiment.
Valneva SE (VALN) Q3 2025 Earnings Call Transcript
Unknown11-20
The earnings call revealed mixed financial performance, with a significant operating loss and negative EBITDA largely due to the absence of last year's PRV sale. While there were improvements in gross margins, the temporary U.S. license suspension for IXCHIQ and unclear FDA timelines add uncertainty. The Q&A highlighted management's lack of specific guidance on key issues like IXCHIQ's suspension and DUKORAL's growth in Germany, leading to a negative sentiment. The absence of clear guidance and the mixed financial results suggest a likely negative stock price reaction.
Valneva SE (VALN) Q2 2025 Earnings Call Transcript
Unknown8-12
The earnings call reveals mixed signals. While there are strong regulatory achievements and promising vaccine developments, the financial performance shows significant operating losses and reduced cash position. Guidance remains steady, but the lack of additional revenue recognition and vague responses in the Q&A highlight uncertainties. The operational cash burn reduction is positive, but overall, the sentiment is balanced by both positive and negative factors, leading to a neutral outlook.
Valneva SE (VALN) Q1 2025 Earnings Call Transcript
Unknown5-9
The earnings call presents a mixed picture. While there is strong sales growth and improved cash burn, the financial health is weakened by operating losses and a net loss. The shareholder return plan is neutral, with a share issuance and reduced cash burn. The Q&A section reveals uncertainties, particularly around regulatory risks and unclear guidance on key metrics. Despite strong financial performance, the market strategy faces competition and regulatory challenges. Overall, the sentiment is neutral, with no strong catalysts for significant short-term stock price movement.
VALN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
